Pilot to validate in vivo 2-HG MR spectroscopy in low grade gliomas

Completed

• Conditions: Low grade glioma; brain tumour; 10029211

• Registration Number: NL-OMON46642
• Lead Sponsor: afdeling Radiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Patients with a low grade glioma >= 18 years old that are planned to undergo surgery and have given written informed consent

Exclusion Criteria

- Patients with recent cerebral radiotherapy or surgery (<3 months)
- Age < 18 years
- General contra-indications for MRI which are non-MRI compatible ferromagnetic material, pregnancy (or possible pregnancy) and claustrophobia.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint is firstly the correlation between the presence of the IDH<br /><br>mutation and the presence of the 2-HG peak on MR spectroscopy (binary<br /><br>variables). Also primary endpoint is the correlation between the concentration<br /><br>of 2-HG on in vivo MR spectroscopy and ex vivo in the tissue in mmol/mg<br /><br>(continue variables).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>